Cargando…

The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis

Current treatment of rheumatoid arthritis (RA) is limited by relative shortage of treatment targets. HM-3 is a novel anti-RA polypeptide consisting of 18 amino acids with integrin αVβ3 and α5β1 as targets. Previous studies confirmed that HM-3 effectively inhibited the synovial angiogenesis and the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ruijing, Li, Jian, Wang, Yibo, Zhang, Lihua, Ma, Xiaohui, Wang, Hongyu, Li, Wenlei, Cao, Xiaodan, Xu, Hanmei, Hu, Jialiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163367/
https://www.ncbi.nlm.nih.gov/pubmed/30201867
http://dx.doi.org/10.3390/ijms19092683
_version_ 1783359344016883712
author Huang, Ruijing
Li, Jian
Wang, Yibo
Zhang, Lihua
Ma, Xiaohui
Wang, Hongyu
Li, Wenlei
Cao, Xiaodan
Xu, Hanmei
Hu, Jialiang
author_facet Huang, Ruijing
Li, Jian
Wang, Yibo
Zhang, Lihua
Ma, Xiaohui
Wang, Hongyu
Li, Wenlei
Cao, Xiaodan
Xu, Hanmei
Hu, Jialiang
author_sort Huang, Ruijing
collection PubMed
description Current treatment of rheumatoid arthritis (RA) is limited by relative shortage of treatment targets. HM-3 is a novel anti-RA polypeptide consisting of 18 amino acids with integrin αVβ3 and α5β1 as targets. Previous studies confirmed that HM-3 effectively inhibited the synovial angiogenesis and the inflammatory response. However, due to its short half-life, the anti-RA activity was achieved by frequent administration. To extend the half-life of HM-3, we designed a fusion protein with name HM-3-Fc, by combination of modified Fc segment of immunoglobulin 4 (IgG4) with HM-3 polypeptide. In vitro cell experiments demonstrated that HM-3-Fc inhibited the proliferation of splenic lymphocytes and reduced the release of TNF-α from macrophages. The pharmacodynamics studies on mice paw in Collagen-Induced Arthritis (CIA) model demonstrated that HM-3-Fc administered once in 5 days in the 50 and 25 mg/kg groups, or once in 7 days in the 25 mg/kg group showed a better protective effect within two weeks than the positive control adalimumab and HM-3 group. Preliminary pharmacokinetic studies in cynomolgus confirmed that the in vivo half-life of HM-3-Fc was 15.24 h in comparison with 1.32 min that of HM-3, which demonstrated that an Fc fusion can effectively increase the half-life of HM-3 and make it possible for further reduction of subcutaneous injection frequency. Fc-HM-3 is a long-acting active molecule for RA treatment.
format Online
Article
Text
id pubmed-6163367
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61633672018-10-10 The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis Huang, Ruijing Li, Jian Wang, Yibo Zhang, Lihua Ma, Xiaohui Wang, Hongyu Li, Wenlei Cao, Xiaodan Xu, Hanmei Hu, Jialiang Int J Mol Sci Article Current treatment of rheumatoid arthritis (RA) is limited by relative shortage of treatment targets. HM-3 is a novel anti-RA polypeptide consisting of 18 amino acids with integrin αVβ3 and α5β1 as targets. Previous studies confirmed that HM-3 effectively inhibited the synovial angiogenesis and the inflammatory response. However, due to its short half-life, the anti-RA activity was achieved by frequent administration. To extend the half-life of HM-3, we designed a fusion protein with name HM-3-Fc, by combination of modified Fc segment of immunoglobulin 4 (IgG4) with HM-3 polypeptide. In vitro cell experiments demonstrated that HM-3-Fc inhibited the proliferation of splenic lymphocytes and reduced the release of TNF-α from macrophages. The pharmacodynamics studies on mice paw in Collagen-Induced Arthritis (CIA) model demonstrated that HM-3-Fc administered once in 5 days in the 50 and 25 mg/kg groups, or once in 7 days in the 25 mg/kg group showed a better protective effect within two weeks than the positive control adalimumab and HM-3 group. Preliminary pharmacokinetic studies in cynomolgus confirmed that the in vivo half-life of HM-3-Fc was 15.24 h in comparison with 1.32 min that of HM-3, which demonstrated that an Fc fusion can effectively increase the half-life of HM-3 and make it possible for further reduction of subcutaneous injection frequency. Fc-HM-3 is a long-acting active molecule for RA treatment. MDPI 2018-09-10 /pmc/articles/PMC6163367/ /pubmed/30201867 http://dx.doi.org/10.3390/ijms19092683 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Ruijing
Li, Jian
Wang, Yibo
Zhang, Lihua
Ma, Xiaohui
Wang, Hongyu
Li, Wenlei
Cao, Xiaodan
Xu, Hanmei
Hu, Jialiang
The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
title The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
title_full The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
title_fullStr The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
title_full_unstemmed The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
title_short The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
title_sort protective effect of a long-acting and multi-target hm-3-fc fusion protein in rheumatoid arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163367/
https://www.ncbi.nlm.nih.gov/pubmed/30201867
http://dx.doi.org/10.3390/ijms19092683
work_keys_str_mv AT huangruijing theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT lijian theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT wangyibo theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT zhanglihua theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT maxiaohui theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT wanghongyu theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT liwenlei theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT caoxiaodan theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT xuhanmei theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT hujialiang theprotectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT huangruijing protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT lijian protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT wangyibo protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT zhanglihua protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT maxiaohui protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT wanghongyu protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT liwenlei protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT caoxiaodan protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT xuhanmei protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis
AT hujialiang protectiveeffectofalongactingandmultitargethm3fcfusionproteininrheumatoidarthritis